Swiss cannabis business & industry — knowledge hub

How the Swiss cannabis market is legally divided

Anyone wishing to do business with cannabis in Switzerland does not operate in a single market, but in four clearly separated legal frameworks — and confusing these frameworks is the most common and expensive mistake made by new market entrants. The first framework is the free market for products under 1 % total THC: CBD flowers, oils, cosmetics. No narcotics license is required here, but depending on the product category, compliance with food, cosmetics, or tobacco law is necessary. The second framework is medical cannabis over 1 %, which, since the revision of the law on 1 August 2022, can be prescribed by doctors without an exceptional permit from the BAG, but requires a Swissmedic license for manufacturing.

The third framework consists of the pilot trials under Art. 8b BetmG: time-limited, scientifically monitored studies with controlled sales to a closed, registered group of participants. This is not an open market, but a research framework with a fixed number of participants, defined dispensing quantities, and reporting obligations. The fourth framework is the planned regulatory framework of the Cannabis Products Act (CanPG), which is currently in the parliamentary process and is intended to turn the pilot trials into a permanent, licensed market.

For every business idea, the first question is therefore not «is it allowed?», but «which of the four frameworks does it operate in?». The decisive factor is always the total THC, i.e. THC plus THCA multiplied by the factor of 0.877. A product with 0.4 % delta-9-THC and 0.9 % THCA has a total THC content of around 1.19 % and is therefore a narcotic — even if the packaging says «under 1 %».

• Free market (<1 % total THC): no BetmG permit required, but product compliance — novel food status for edibles, cosmetics regulation for topicals, tobacco tax for smoking products
• Medical (>1 %): medical prescription, Swissmedic license for cultivation, manufacturing, and trade
• Pilot trial (Art. 8b): BAG permit, scientific monitoring, closed participant group
• Future CanPG framework: licensing model with quality, youth protection, and advertising requirements — timeline still open

Where the money is actually made in this industry

In Switzerland, value creation is rarely where newcomers expect it to be. The retail flower trade is the most visible but lowest-margin part of the chain: high fixed costs for retail space, staff, and spoilage, combined with price pressure that has continuously driven down retail prices since 2019. Our price index shows CHF 3.80–6.70 per gram in retail for outdoor CBD flowers — with production costs consuming a significant portion of this, depending on the cultivation method.

More robust are positions that have either a permit, a facility, or a customer relationship as a barrier to entry: licensed extraction and contract processing, accredited analytics, genetics and clone production, B2B wholesale with traceability, as well as member and direct sales models that remove the retail margin from the chain. This is precisely what our club model focuses on: purchasing directly from the licensed Swiss producer, pooling demand, no intermediary stage.

Anyone looking for financing should know that Swiss banks continue to treat cannabis companies restrictively — account openings regularly fail due to internal compliance rules, regardless of the legality of the business model. This is a real cost factor that is frequently underestimated in business plans.

How best to use this hub

The subpages of this cluster follow the order in which a project is evaluated in practice: first the market size and whether there is any demand at all, then the licensing question with Swissmedic, then the specific implementation in the chosen segment — CBD, medical, cultivation — and finally financing and the outlook on legalization. Newcomers should read the market size and licensing pages first; those who are already operational will find the specific requirements on the segment pages.

All figures on these pages are to be understood as rough estimates and come from publicly accessible sources as well as our own price index. Swissmedic is responsible for binding information on permits, the BAG for pilot trials, and the BLV for food law issues.

Regulatory Jungle and Licensing Pathways in the Swiss Market

Anyone setting up a cannabis business in Switzerland must precisely delineate the responsibilities of the federal authorities. Swissmedic is responsible for the authorization and monitoring of medicinal products as well as for manufacturing licenses. The Federal Office of Public Health (BAG) regulates the scientific pilot trials and monitors compliance with the Narcotics Act (BetmG). The Federal Food Safety and Veterinary Office (BLV), on the other hand, controls the marketability of CBD-containing foods. A common mistake is submitting applications to the wrong authority, which leads to months of delay and significant additional administrative costs.

Practice shows that licensing procedures place high demands on companies' documentation and quality management systems. Particularly in the medical sector, producers must provide seamless proof that their processes comply with Good Manufacturing Practice (GMP). Every batch must be analyzed by accredited laboratories to determine the exact total THC content. Anyone who underestimates this bureaucratic effort in their business plan often fails before their first market authorization. Early, transparent communication with cantonal therapeutic products authorities and laboratories is essential for project success.

• Swissmedic regulates medical applications and GMP-compliant production facilities.
• The BAG controls the time-limited pilot trials according to Article 8b BetmG.
• The BLV monitors the strict guidelines for CBD foods and cosmetics.
• Cantonal laboratories carry out random checks in the trade.

Federalism in Enforcement: Cantonal Differences for Operators

Although the Narcotics Act (BetmG) is a federal law, enforcement lies largely with the cantons. In practice, this leads to a significant fragmentation of the Swiss market. While some cantons maintain a liberal practice regarding the sale of CBD products, others monitor compliance with labeling requirements and youth protection extremely restrictively. The levying of the fixed penalty fine of one hundred francs on consumers is also handled differently depending on the canton. For founders, this means they must carefully analyze local conditions and the stance of the cantonal authorities.

Another critical point is cooperation with the cantonal therapeutic products inspectorates and economic offices. The approval of operating sites for cultivation or processing depends heavily on the local interpretation of the guidelines. A business model that is approved without any problems in one canton can encounter massive hurdles in a neighboring canton. Companies should therefore not only keep an eye on the federal level, but seek direct dialogue with the cantonal authorities from the very beginning in order to avoid unpleasant surprises during operational audits.

• The interpretation of advertising and youth protection rules varies greatly depending on the canton.
• Cantonal laboratories independently test products for the limit of less than one percent total THC.
• The licensing practice for processing facilities sometimes differs significantly from region to region.
• Local police authorities handle checks in public spaces according to their own priorities.

Operational risks and the relentless road traffic rule

An often overlooked risk for cannabis businesses concerns the mobility of their own employees and customers. In Switzerland, a zero-tolerance policy regarding THC applies to road traffic. The legal detection limit is a mere 1.5 micrograms of THC per litre of blood, which is reached extremely quickly. Even the consumption of legal CBD products with a total THC content of less than one percent can lead to this limit being exceeded. Companies must actively inform their employees, especially in delivery or field services, about this legal reality and the threat of unfitness to drive.

In addition to the traffic law hazards, liability issues also pose significant operational risks. Should a product exceed the legal limit of one percent total THC even minimally, it is legally considered an illegal narcotic immediately. This can result in criminal consequences for the management, the confiscation of the entire inventory, and the immediate revocation of operating licences. Seamless quality management with batch-specific laboratory analyses is therefore not a luxury, but an existential necessity for every market participant in Switzerland.

• Strict zero tolerance in road traffic with a limit of 1.5 micrograms of THC per litre of blood.
• Risk of criminal prosecution in the event of a minimal exceedance of the limit of one percent total THC.
• Existential risks due to official confiscations in the event of incorrect declaration.
• Need for awareness campaigns for employees in the transport and delivery sector.

Financial planning and the real costs of regulatory compliance

Founding a cannabis business in Switzerland requires significantly higher starting capital than in traditional sectors. The biggest cost drivers are not raw materials or infrastructure, but regulatory compliance. Every product batch must be tested by an accredited laboratory for pesticides, heavy metals, and the exact cannabinoid content before sale. These analysis costs quickly add up to several thousand francs per month. Added to this are the fees for cantonal permits, certifications, and legal advice in a constantly changing regulatory environment.

Another financial bottleneck is the ongoing refusal of many Swiss banks to open business accounts for companies in the cannabis sector. Even pure CBD retailers or service providers without direct product contact are often rejected during the compliance checks of financial institutions. This forces companies to switch to more expensive foreign payment service providers or manage significant cash reserves, which in turn poses security risks. Sound financial planning must take these hurdles into account and budget for sufficient liquidity reserves for delays in account opening and official processes.

• High ongoing costs for mandatory laboratory analyses for the quality assurance of each batch.
• Increased administrative effort and fees for cantonal and federal permits.
• Difficulties in opening Swiss bank accounts due to restrictive compliance policies.
• Necessity of substantial liquidity reserves for regulatory delays.

FAQ